Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Omeros Corporation (NASDAQ:OMER) have been given an average recommendation of “Moderate Buy” by the five research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $40.3333.

Several equities research analysts have recently commented on OMER shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Thursday. WBB Securities reaffirmed a “strong-buy” rating and set a $45.00 target price on shares of Omeros in a report on Wednesday, October 15th. HC Wainwright upped their target price on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Thursday, January 8th.

Omeros Stock Performance

NASDAQ:OMER opened at $11.53 on Tuesday. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65. The company has a market cap of $817.48 million, a price-to-earnings ratio of -5.71 and a beta of 2.38. The stock’s fifty day moving average price is $11.72 and its two-hundred day moving average price is $7.38.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.39. On average, equities analysts predict that Omeros will post -3.09 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CAO David J. Borges sold 30,000 shares of the firm’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 12.90% of the company’s stock.

Institutional Investors Weigh In On Omeros

A number of hedge funds have recently modified their holdings of OMER. B. Riley Wealth Advisors Inc. acquired a new position in shares of Omeros in the 2nd quarter valued at approximately $32,000. Harbour Investments Inc. lifted its stake in Omeros by 46.1% in the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 4,251 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 11,971 shares during the period. Sei Investments Co. acquired a new position in shares of Omeros in the second quarter valued at approximately $40,000. Finally, Russell Investments Group Ltd. increased its position in shares of Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 5,677 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.